Pharma patient assistance programs do not have enough data to support them.


“If the US government is going to accept pharmaceutical companies’ statement that India and
other countries’ policies are not needed to ensure access to medicines, and that the companies’
assistance programs fully provide the drugs needed by their populations, then the government
should have full data on these programs. If the US government wants to accept that donation
programs solve all the access problems in developing countries, then it needs to know the actual
number of patients that need the drugs and are then able to have access to it. This information
needs to be available in order for them to make informed and accurate decisions.”

 

http://keionline.org/sites/default/files/Claire_Cassedy_KEI_Comments_on_Patient_Assistance_Programs_Special301_7March2014.pdf

Cassedy, Claire; Reply Comments of Claire Cassedy , regarding drug company patient assistance programs, USTR docket # USTR­2013­0040, Special 301. March, 2014.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s